AARD vs RYTM
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule treatments for metabolic diseases and Prader-Willi Syndrome. RYTM: Rhythm Pharmaceuticals is a biopharmaceutical company specializing in precision therapies for rare genetic and neuroendocrine disorders characterized by severe obesity and hyperphagia.
Side-by-side fundamentals
| Metric | AARD | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $3.90 | $90.20 | |
| Market cap | $85M | $6.2B | |
| Net margin FY2025, SEC XBRL | n/a | -103.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -101.2% | |
| ROE FY2025, SEC XBRL | -54.0% | -141.3% | AARD higher |
| ROA FY2025, SEC XBRL | -49.1% | -40.9% | RYTM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 1.03 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +45.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +100.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.93 | 0.86 | |
| 1-year return as of 2026-10-20 close | -68.2% | -19.7% | RYTM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.